Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.8 USD | -1.23% | +10.69% | +140.44% |
05-29 | Baird Starts Mind Medicine (MindMed) With Outperform Rating, $27 Price Target | MT |
05-13 | Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+140.44% | 633M | |
+52.36% | 58.06B | |
-3.86% | 40.53B | |
+36.81% | 38.99B | |
+14.13% | 26.7B | |
-12.01% | 26.56B | |
-21.62% | 18.98B | |
+0.21% | 12.17B | |
+23.02% | 12B | |
+25.96% | 11.92B |
- Stock Market
- Equities
- MNMD Stock
- News Mind Medicine (MindMed) Inc.
- Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024